公开(公告)号：US09580506B2

公开(公告)日：2017-02-28

申请号：US11989064

申请日：2006-07-21

Applicant: Catharina Emanuele Gerarda Havenith ,  Tom Vink ,  Patrick Van Berkel ,  Paul Parren

Inventor： Catharina Emanuele Gerarda Havenith ,  Tom Vink ,  Patrick Van Berkel ,  Paul Parren

IPC: G01N33/53 ,  C07K16/28 ,  G01N33/566 ,  C07K16/00

CPC classification number: C07K16/2812 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/732 ,  C07K2317/76 ,  G01N33/566 ,  G01N2333/70535

Abstract: The invention relates to a method of characterizing an antibody, which method is suitable as a potency assay for batch release of a pharmaceutical composition comprising an antibody, specifically for use when applying for marketing authorization for said pharmaceutical composition. The assay provided is a method for determining the potency of a drug product comprising an FcR binding peptide, wherein at least one mechanism of action of the FcR binding peptide of the drug product is mediated through the binding of the FcR binding peptide of the drug product to a Fc receptor, wherein said method comprises determining the binding of the FcR binding peptide of the drug product to an Fc receptor.

Abstract translation: 本发明涉及一种表征抗体的方法，该方法适用于批量释放包含抗体的药物组合物的效力测定，该抗体特别用于在申请所述药物组合物的营销授权时使用。 提供的测定法是用于测定包含FcR结合肽的药物产品的效力的方法，其中药物产物的FcR结合肽的至少一种作用机制是通过药物产物的FcR结合肽的结合来介导的 其中所述方法包括测定药物产物的FcR结合肽与Fc受体的结合。

公开(公告)号：US09540450B2

公开(公告)日：2017-01-10

申请号：US14199391

申请日：2014-03-06

Applicant: GENMAB A/S

Inventor： Jan Van De Winkel ,  Paul Parren ,  Willem Karel Bleeker ,  Klaus Edvardsen ,  Jeroen Lammerts Van Bueren ,  Thomas Valerius ,  Michael Dechant ,  Wencke Weisner ,  Sven Berger

IPC: C07K16/28 ,  C07K16/40 ,  C07K16/44 ,  C07K16/46 ,  G01N33/573 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/573

Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.

Abstract translation: 本发明涉及用于治疗肿瘤的新方法，包括施用双特异性抗体或两种或多种识别相同靶抗原或抗原复合物的非交叉阻断抗体的组合。 特别地，本发明涉及用于诱导补体介导的细胞杀伤治疗肿瘤的方法，所述方法包括向有需要的人共同施用第一抗体和第二抗体，其中所述第一抗体 结合EGFR，所述第二抗体结合EGFR，所述第一和第二抗体是非交叉阻断的，并且所述给药方案使得在肿瘤部位获得CDC。

公开(公告)号：US09458236B2

公开(公告)日：2016-10-04

申请号：US14055222

申请日：2013-10-16

Applicant: GENMAB A/S

Inventor： Jan G. J. Van De Winkel ,  Marcus Antonius Van Dijk ,  Edward Halk ,  Arnout F. Gerritsen ,  Jørgen Petersen ,  Ole Baadsgaard

IPC: A61K39/395 ,  C07K16/28 ,  C07H21/04 ,  G01N33/53 ,  A61K45/06 ,  A61K47/48 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A01K2217/05 ,  A01K2217/075 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56966

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US09322035B2

公开(公告)日：2016-04-26

申请号：US12602419

申请日：2008-05-30

Applicant: Janine Schuurman ,  Tom Vink ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Paul Parren ,  Willem Karel Bleeker ,  Frank Beurskens ,  Patrick Van Berkel

Inventor： Janine Schuurman ,  Tom Vink ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Paul Parren ,  Willem Karel Bleeker ,  Frank Beurskens ,  Patrick Van Berkel

IPC: C07K16/00 ,  C12N15/85 ,  C07K16/28

CPC classification number: C07K16/2887 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/283 ,  C07K16/2863 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/732 ,  C07K2317/77 ,  C07K2317/90 ,  C12N15/8509 ,  C12N2740/16011

Abstract: The invention relates to novel non-human transgenic animals, which upon antigenic stimulation are capable of producing monovalent antibodies binding to a selected antigen, modified heavy chain transgenes, methods for producing the non-human transgenic animals, methods for immunizing the non-human transgenic animals for as well as monovalent antibodies obtainable by such immunization methods.

Abstract translation: 本发明涉及新型非人转基因动物，其在抗原刺激时能够产生结合选定抗原的单价抗体，修饰的重链转基因，用于产生非人转基因动物的方法，用于免疫非人转基因动物的方法 动物以及通过这种免疫方法可获得的单价抗体。

公开(公告)号：US09187565B2

公开(公告)日：2015-11-17

申请号：US12886930

申请日：2010-09-21

Applicant: Michel De Weers ,  Yvo Graus ,  Judith Oprins ,  Paul Parren ,  Jan Van De Winkel ,  Martine Van Vugt

Inventor： Michel De Weers ,  Yvo Graus ,  Judith Oprins ,  Paul Parren ,  Jan Van De Winkel ,  Martine Van Vugt

IPC: A61K38/00 ,  C07K16/28 ,  C07K14/705 ,  A61K39/00

CPC classification number: C07K16/40 ,  A61K39/3955 ,  A61K45/06 ,  A61K49/0004 ,  A61K2039/505 ,  C07K14/70596 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  G01N33/566 ,  G01N2333/70596

Abstract: Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US09085625B2

公开(公告)日：2015-07-21

申请号：US13132423

申请日：2009-12-03

Applicant: Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jau Van De Winkel ,  Janine Schuurman ,  Lgnace Laster

Inventor： Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jau Van De Winkel ,  Janine Schuurman ,  Lgnace Laster

IPC: C07K16/00 ,  C07K16/28

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/103 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/76

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

Abstract translation: 本发明涉及抗体的恒定区，特别是IgG4的CH3区的位置，其影响了CH3-CH3相互作用的强度。 公开了稳定或不稳定这种相互作用的突变。

公开(公告)号：US09040050B2

公开(公告)日：2015-05-26

申请号：US12442808

申请日：2007-09-26

Applicant: Jan Van De Winkel ,  Paul Parren ,  Yvo Graus ,  Judith Oprins ,  Michel De Weers ,  Martine Van Vugt ,  Ole Baadsgaard ,  Steen Lisby

Inventor： Jan Van De Winkel ,  Paul Parren ,  Yvo Graus ,  Judith Oprins ,  Michel De Weers ,  Martine Van Vugt ,  Ole Baadsgaard ,  Steen Lisby

IPC: A61K39/395 ,  C07K16/28 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2896 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/34 ,  A61K2300/00

Abstract: The invention relates to novel method for the treatment of cancer using a combination therapy comprising an antibody that binds CD38, a corticosteroid and a non-corticosteroid chemotherapeutic agent.

Abstract translation: 本发明涉及使用包含结合CD38的抗体，皮质类固醇和非皮质类固醇化学治疗剂的组合疗法治疗癌症的新方法。

公开(公告)号：US20140348833A1

公开(公告)日：2014-11-27

申请号：US14199391

申请日：2014-03-06

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Paul PARREN ,  Willem Karel BLEEKER ,  Klaus EDVARDSEN ,  Jeroen Lammerts VAN BUEREN ,  Thomas VALERIUS ,  Michael DECHANT ,  Wencke WEISNER ,  Sven BERGER

IPC: C07K16/40 ,  G01N33/573 ,  C07K16/46

CPC classification number: C07K16/40 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/573

Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.

Abstract translation: 本发明涉及用于治疗肿瘤的新方法，包括施用双特异性抗体或两种或多种识别相同靶抗原或抗原复合物的非交叉阻断抗体的组合。 特别地，本发明涉及用于诱导补体介导的细胞杀伤治疗肿瘤的方法，所述方法包括向有需要的人共同施用第一抗体和第二抗体，其中所述第一抗体 结合EGFR，所述第二抗体结合EGFR，所述第一和第二抗体是非交叉阻断的，并且所述给药方案使得在肿瘤部位获得CDC。

公开(公告)号：US20140141006A1

公开(公告)日：2014-05-22

申请号：US14055222

申请日：2013-10-16

Applicant: Genmab A/S

Inventor： Jan G. J. VAN DE WINKEL ,  Marcus Antonius VAN DIJK ,  Edward HALK ,  Arnout F. GERRITSEN ,  Jørgen PETERSEN ,  Ole BAADSGAARD

IPC: C07K16/28 ,  G01N33/569 ,  A61K45/06 ,  A61K39/395 ,  A61K47/48

CPC classification number: C07K16/2863 ,  A01K2217/05 ,  A01K2217/075 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56966

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与人EGFR特异性结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20130209355A1

公开(公告)日：2013-08-15

申请号：US13702857

申请日：2011-06-08

Applicant: Michel De Weers ,  Tim Walseth ,  Jan Van De Winkel ,  Tom Vink ,  Paul Parren

Inventor： Michel De Weers ,  Tim Walseth ,  Jan Van De Winkel ,  Tom Vink ,  Paul Parren

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/76 ,  G01N33/573 ,  G01N2333/91148

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

Abstract translation: 公开了结合人CD38和相关的基于抗体的组合物和分子的分离的单克隆抗体。 还公开了包含抗体的药物组合物和使用抗体的治疗和诊断方法。